Sign In
Buy PTC
$139.72
-2.62 (-1.84%)
At Close: Jun 03, 2026
PTC Expands Onshape Portfolio to Transform Product Design & Compliance
09:51am, Wednesday, 16'th Apr 2025
PTC introduces Onshape AI Advisor and Onshape Government for designers, engineers, educators and professionals in regulated industries.
PTC Continues Onshape Momentum with Release of Onshape AI Advisor and Onshape Government
08:30am, Tuesday, 15'th Apr 2025
New AI-powered assistant offers designers step-by-step guidance and recommendations during design process Onshape Government delivers cloud-native CAD and PDM to aerospace and defense companies with I
PTC to Announce Fiscal Q2'25 Results on Wednesday, April 30th, 2025
07:00am, Wednesday, 09'th Apr 2025
BOSTON , April 9, 2025 /PRNewswire/ -- PTC (Nasdaq: PTC) will release its fiscal 2025 second quarter results on Wednesday, April 30 th after the stock market closes. Senior management will host a liv
PTC Strengthens ALM and Systems Engineering Focus with Acquisition of IncQuery Group
08:00am, Wednesday, 02'nd Apr 2025
BOSTON , April 2, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the acquisition of IncQuery Group. IncQuery Group offers application lifecycle management (ALM) and systems engineering develop
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 28'th Mar 2025
WARREN, N.J. , March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 24, 2025, the company approved non-statutory stock options to purchase an aggregate o
PTC Launches Codebeamer 3.0 to Boost Speed, Quality & Sustainability
12:05pm, Friday, 28'th Mar 2025
PTC launches Codebeamer 3.0 to speed up product development, boost sustainability and ensure quality and compliance with full traceability and smarter tools.
PTC Therapeutics says European Commission will remove muscle disorder drug
09:20am, Friday, 28'th Mar 2025
PTC Therapeutics said on Friday the European Commission will remove its inherited progressive muscle-wasting disorder from the region after an advisory panel reaffirmed a negative opinion of the drug
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
09:00am, Friday, 28'th Mar 2025
WARREN, N.J. , March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products
PTC Launches Codebeamer 3.0
08:30am, Thursday, 27'th Mar 2025
Industry-leading ALM solution delivers enhanced speed and scalability with variant management Modern branching method and scaled working sets enable customers to accelerate development of products and
PTC's Premium Valuation Justified By Strong Outlook, Buy On Dips
06:23am, Thursday, 27'th Mar 2025
PTC basically offers end-to-end software solutions for managing the product lifecycle across diverse industries. Their flagship platforms are Windchill, Codebeamer, ServiceMax, and Creo, which overall
PTC to Showcase Windchill AI at Hannover Messe 2025: Stock to Gain?
11:20am, Wednesday, 26'th Mar 2025
PTC will unveil Windchill AI, Codebeamer AI and ServiceMax AI at Hannover Messe 2025, promising innovation and fostering digital transformation.
PTC Brings AI-Powered PLM to Hannover Messe 2025 with Windchill AI
08:30am, Tuesday, 25'th Mar 2025
PTC to preview Windchill AI and Document Vault AI agent PTC to demonstrate agentic AI across the product digital thread with Windchill AI, Codebeamer AI, and ServiceMax AI PTC demonstrations available
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
08:00am, Thursday, 20'th Mar 2025
— Results show 97% of phenylalanine (Phe) tolerance study participants were able to increase their dietary Phe intake with a mean increase of 126% — — Genetic variant analysis of Phase 3 APHENI
PTC Appoints Trac Pham to Board of Directors
04:00pm, Thursday, 13'th Mar 2025
BOSTON , March 13, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it has appointed Trac Pham to its Board of Directors, effective March 17, 2025. Pham is the former Chief Financial Offi
PTC Therapeutics: Upside In Rare Disease Innovation
09:47am, Sunday, 09'th Mar 2025
PTC Therapeutics is poised for a potential turnaround with key FDA reviews in 2025 for vatiquinone and sepiapterin, despite past revenue declines. The company maintains a strong cash position of over
